Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Generalized Anxiety Disorder Market is Estimated to Grow at 2.5% CAGR to Reach $7.5 Billion by 2023

This image opens in the lightbox

News provided by

IndustryARC

10 Apr, 2018, 14:45 GMT

Share this article

Share toX

Share this article

Share toX

HYDERABAD, India, April 10, 2018 /PRNewswire/ --

According to the new market research report by IndustryARC titled "Generalized Anxiety Disorder Market: By Therapeutics Type (Antidepressant, Benzodiazepines, Others (Buspirone)) & Geography (Europe, Asia Pacific, North America, Rest of the World)-Forecast (2018-2023)" , the market is estimated to grow at 2.5% CAGR to reach $7.5 billion by 2023.

     (Logo: https://mma.prnewswire.com/media/660951/IndustryARC_Logo.jpg )

North America continues to lead the market share during 2018-2023.  

North America held the major share in global generalized anxiety disorder market, followed by Europe and Asia-Pacific region in terms of revenue. In North America, Mexico is the leading country with 2.5% compound annual growth rate (CAGR) followed by Canada and the U.S. with 2.0% and 1.5% CAGR respectively in 2017. In Canada, the number of depression cases is likely to increase with the adoption of sedentary lifestyles. This has brought forward the newfound demand for development of therapeutics and is more likely to have a positive impact on the demand and growth for generalized anxiety disorder market.

The developments in mental health-care services and rising awareness towards anxiety disorders are responsible for the increase in the diagnosis of GAD in this region. The growing geriatric population is increasing the anxiety diagnosis rates in Mexico, thus directly boosting the demand for physiotherapies such as Cognitive Behavior Therapy (CBT) and GAD medication.

The sedentary lifestyle and stressful work environments are the major factors for the growing incidence of anxiety disorders in the U.S. According to Anxiety and Depression Association of America (ADAA), nearly 6.8 million people accounting to 3.1% of total population is affected by GAD every year. Moreover, the approval of several drugs including antidepressant drugs such as Paroxetine and Escitalopram, and benzodiazepine sedatives such as Alprazolam and Clonazepam is promising for the growth of therapeutic drugs in the U.S.

Anxiety and depressive disorders emerged as the two most common psychiatric illnesses across the globe. According to WHO, Brazil has the highest prevalence of anxiety disorders in the world and the country ranks fifth in depression disorders. The Asia-Pacific region is estimated to witness fastest growth rate to reach $1.8 billion with a CAGR of 3.8% by 2023. It is expected to register healthy growth especially from India and China owing to the rising healthcare expenditure coupled with growing number of geriatric population with depression, anxiety and panic disorders. The transition of psychiatric services in Japan towards adoption of standardized diagnostic criteria and advanced antidepressant drugs such as selective serotonin, reuptake inhibitors are also increasing the prevalence of GAD.

To purchase or browse the table of contents of the report follow the link below:  

https://industryarc.com/Report/15869/generalized-anxiety-disorder-market.html

Excerpts on Market Growth Factors Mentioned in the Full Report:  

  1. Generalized anxiety disorder market is experiencing growth globally owing to the rising instances of depression and global anxiety disorders among working class population due to extreme stress and busy lifestyles.
  2. Aggregating healthcare expenditure coupled with the increasing number of FDA approved drugs for treating anxiety disorders is providing opportunities for manufactures to invest in research and product development of these drugs and expand their product portfolio.
  3. Increasing stress and sedentary lifestyle is increasing the number of patients suffering from GAD and thus, driving the market growth globally.
  4. Technological advancement in the pharmaceutical industry is slated to provide significant opportunity to the generalized anxiety disorder market.
  5. Additionally, increasing public and private partnerships in the healthcare sector for R&D of generalized anxiety disorder drugs offers opportunity in the coming future for the GAD market.

Request for table of contents of the full report by providing your details in the link below:

https://industryarc.com/pdfdownload.php?id=15869

Sample Key Players of the Generalized Anxiety Disorder Market:  

Pfizer, Inc. and Eli Lilly and Company are analyzed to be the dominant players of the Generalized Anxiety Disorder market. The top 5 companies constitute more than 50% share in the total market globally. Acquisitions and partnerships are the key strategies adopted by the companies to enhance their market share.

Companies Cited/Referred/Interviewed:  

  1. Abbott Laboratories
  2. F-Hoffmann-La Roche
  3. Shionogi and company
  4. Allergan plc
  5. GlaxoSmithKline plc.
  6. Sumitomo Dainippon Pharma Co., Ltd.
  7. Bristol-Myers Squibb Company
  8. Noven Pharmaceuticals, Inc.
  9. Company 9
  10. Company 10
  11. Company 11
  12. Company 12
  13. Others (10+)

Generalized Anxiety Disorder Market Report is Segmented as indicated below.  

  • Generalized Anxiety Disorder Market by Therapeutics Type:

1. Antidepressants

    1.1 Selective Serotonin Reuptake Inhibitors (SSRI)

    1.2 Serotonin Norepinephrine Reuptake Inhibitors (SNRI)

2. Benzodiazepines

   2.1 Alprazolam

   2.2 Chlordiazepoxide

   2.3 Diazepam

   2.4 Lorazepam

3. Others (Buspirone)

• Generalized Anxiety Disorder Market By Geography (Covers 15+ Countries )

• Generalized Anxiety Disorder Market Entropy

• Company Profiles

• Appendix: Abbreviations, Sources, Research Methodology, Bibliography, Compilation of Experts, Disclaimer.

What can you expect from the report? 

The Generalized Anxiety Disorder Market Report is Prepared with the Main Agenda to Cover the following 20 points:

  • Market Size by Product Categories
  • Market trends
  • Manufacturer Landscape
  • Distributor Landscape
  • Pricing Analysis
  • Top 10 End user Analysis
  • Product Benchmarking
  • Product Developments
  • Mergers & Acquisition Analysis
  • Patent Analysis
  • Demand Analysis (By Revenue & Volume)
  • Country level Analysis (15+)
  • Competitor Analysis
  • Market Shares Analysis
  • Value Chain Analysis
  • Supply Chain Analysis
  • Strategic Analysis
  • Current & Future Market Landscape Analysis
  • Opportunity Analysis
  • Revenue and Volume Analysis

Frequently Asked Questions:  

Does IndustryARC publish country, geography or application-based reports in Generalized Anxiety Disorder?  

Yes, we do have separate reports and database as mentioned below:

1. North America Market for Generalized Anxiety Disorder (2018-2023)

2. Asia-Pacific Market for Generalized Anxiety Disorder (2018-2023)

3. Europe Market for Generalized Anxiety Disorder (2018-2023)

4. Antidepressant Market for Generalized Anxiety Disorder (2018-2023)

5. Benzodiazepines Market for Generalized Anxiety Disorder (2018-2023)

Does IndustryARC provide customized reports and charge additionally for limited customization?  

Yes, we can customize the report by extracting data from our database of reports and annual subscription databases. We can provide the following free customization:

1. Increase the level of data in application or end user industry.

2. Increase the number of countries in geography or product chapter.

3. Find out market shares for other smaller companies or companies which are of interest to you.

4. Company profiles can be requested based on your interest.

5. Patent analysis, pricing, product analysis, product benchmarking, value and supply chain analysis can be requested for a country or end use segment.

Any other major customizations can be discussed with our team, we can provide a separate quote based on your requirements. You can drop in an e-mail to sales@industryarc.com to discuss more about our consulting services.

To request for a proposal, provide your details in the below link:

https://industryarc.com/subscription.php

About IndustryARC:  

IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences &Healthcare.

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications in a Market. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business.

We look forward to support the client to be able to better address their customer needs, stay ahead in the market, become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.

Media Contact:
Mr. Venkat Reddy
Sales Manager
Email 1: sales@industryarc.com
Or Email 2: venkat@industryarc.com
Contact Sales: +1-614-588-8538 (Ext-101)

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.